ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 102 filers reported holding ASCENDIS PHARMA A/S in Q2 2018. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $18,263 | +20.0% | 145 | +2.1% | 0.00% | – |
Q1 2023 | $15,225 | -75.0% | 142 | -71.5% | 0.00% | -100.0% |
Q4 2022 | $60,821 | +452.9% | 498 | +507.3% | 0.00% | – |
Q2 2021 | $11,000 | -91.1% | 82 | -88.9% | 0.00% | -100.0% |
Q4 2020 | $123,000 | +2.5% | 737 | -4.9% | 0.01% | -16.7% |
Q3 2020 | $120,000 | – | 775 | +19275.0% | 0.01% | – |
Q1 2020 | $0 | -100.0% | 4 | -94.9% | 0.00% | -100.0% |
Q3 2019 | $9,000 | 0.0% | 78 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $9,000 | +800.0% | 78 | +766.7% | 0.00% | – |
Q3 2018 | $1,000 | 0.0% | 9 | 0.0% | 0.00% | – |
Q2 2018 | $1,000 | – | 9 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |